









Markets
/
Stocks
/
nasdaq-orka
/

Oruka Therapeutics Inc

ORKA

26.580USD

+0.390+1.49%

Market hours （ET）Quotes delayed by 15 min

995.44MMarket Cap

LossP/E TTM



Oruka Therapeutics Inc

26.580

+0.390+1.49%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Oruka Therapeutics Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Oruka Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

89 / 407

Overall Ranking

202 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

44.545

Target Price

+58.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Oruka Therapeutics Inc Highlights

StrengthsRisks

Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -11.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 37.99M shares, increasing 3.94% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 2.67M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.81, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.81

Change



Financials

3.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Oruka Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -11.92, which is -86.84% below the recent high of -1.57 and -7.56% above the recent low of -12.82.

Score

Industry at a Glance

Previous score

6.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 9.17, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Oruka Therapeutics Inc is 44.00, with a high of 60.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

9.20

Change

-0.03

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

44.545

Target Price

+58.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Oruka Therapeutics Inc

ORKA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 9.16, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 30.47 and the support level at 20.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.62

Change

-0.46

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.698

Neutral

RSI(14)

58.237

Neutral

STOCH(KDJ)(9,3,3)

46.078

Sell

ATR(14)

1.795

Low Volatility

CCI(14)

-95.028

Neutral

Williams %R

75.182

Sell

TRIX(12,20)

1.613

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

27.504

Sell

MA10

27.361

Sell

MA20

26.462

Buy

MA50

20.370

Buy

MA100

16.975

Buy

MA200

13.904

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.62M

+0.99%

VR Adviser, LLC

4.15M

Fairmount Funds Management LLC

3.71M

+9.89%

Viking Global Investors LP

Star Investors

2.67M

RTW Investments L.P.

1.95M

Deep Track Capital LP

1.92M

+1.16%

BlackRock Institutional Trust Company, N.A.

1.83M

+150.66%

The Vanguard Group, Inc.

Star Investors

1.82M

+10.99%

Braidwell LP

1.52M

-3.03%

Commodore Capital LP

1.42M

Risk Assessment

Currency: USD Updated: 2025-11-03

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is -0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.